Certificate PL-26-00092 · Semaglutide 15 mg · lot PL-2609-092
VerifyCertificate page
PrymaLab
PrymaLab
PrymaLab Analytical · In-house laboratory
3705 Music Branch Rd, Ashland, KY 41102 · +1 (606) 465-9063 · prymalab.net
Certificate no.
PL-26-00092
Verification key
UAG54Y54
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release

Semaglutide 15 mg

Lot PL-2609-092 · Lyophilized powder · Label claim 15 mg/vial
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2609-092
Date made
2026-09-18
Date of analysis
2026-09-19
Date issued
2026-10-03
Retest / expiry
2028-09-18
Units in lot / sampled
350 / 3
Storage
−20 °C, desiccated, dark
Certificate type
Lot COA, 2 pages
Compound
Semaglutide
NN9535; GLP-1 receptor agonist
CAS number
910463-68-2
Molecular formula
C187H291N45O59
Theoretical mass (avg.)
4113.6 Da
Sequence
H-H-Aib-EGTFTSDVSSYLEGQAAK(2×OEG-γGlu-C18 diacid)EFIAWLVRGRG-OH (31 residues; Aib8 and Arg34 in GLP-1 numbering; Lys26 acylated with octadecanedioic acid via two OEG spacers and γ-Glu; free C-terminus)
Purity · RP-HPLC, area %
99.31%
Specification 99.0% • main peak at 7.95 min
Identity · Observed Mass
4113.8 Da
Theoretical 4113.6 Da • +0.2 Da (49 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
AppearanceVisual inspectionWhite to off-white lyophilized powderWhite lyophilized powderPASS
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da4113.8 DaPASS
PurityRP-HPLC, UV 214 nm, area%99.0%99.31%PASS
Largest impurityRP-HPLC, area%1.0%0.22% at 7.22 min (Asp 15 →isoAsp isomerization)PASS
Water contentKarl Fischer5.0%1.7%PASS
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.05 EU/mgPASS
Sterility / bioburdenUSP <71>, membrane filtrationNo growth after 14 daysNo growth; conformsPASS

1HPLC chromatogram

Data file: SEM_PL-2609-092_20260919_01 · Column C18, 150 × 4.6 mm · UV 214 nm
0 150 300 mAU 024 681012 Time (min) Semaglutide — 99.31% @ 7.95 min 0.12% @ 5.52 0.16% @ 6.91 0.22% @ 7.22 0.19% @ 7.52
Baseline uncropped; main peak and impurities labeled with retention times. Peak table on page 2.
PrymaLab
PrymaLab
Certificate of Analysis · continued
Semaglutide 15 mg · Lot PL-2609-092 · Certificate PL-26-00092
Lot PL-2609-092
Method, peak table and approval

2HPLC method · SEM_PL-2609-092_20260919_01

Instrument
Waters Alliance e2695, SN E2695B742
Data System
Empower 3, Build 3471
Detector
Waters 2998 PDA
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Column Part / Serial
186003326 / USHX21100
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
20 µL
Run Time
12 min
Sample Diluent
0.1% TFA in 30% MeCN
Sample Concentration
0.5 mg/mL
Blank Injected
Yes
Reference Standard
In-house Semaglutide reference, lot PL-RS-SEM-01, RT 7.92 min

3Gradient program

Time (min)% A% B
0.06535
2.06535
9.02575
10.01585
11.01585
12.06535

4Peak table

PeakRT (min)AreaArea %
15.524,9370.12
2 (deamid.)6.916,5820.16
3 (isoAsp)7.229,0500.22
4 (Trp-ox)7.527,8160.19
57.954,085,41599.31
Total4,113,800100.00
Threshold 0.05% area · Blank subtracted: Y · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters Acquity SQD
Ionization / Mode
ESI, positive
Observed m/z (charge)
823.8 (5+ [M+5H]) · 686.6 (6+ [M+6H])
Deconvoluted Mass
4113.8 Da
Theoretical Mass
4113.6 Da
Difference
+0.2 Da (49 ppm)
Data File
SEM_PL-2609-092_MS_20260919_01
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Water contentPrymaLab2026-09-19RPT-KF-PL-2609-092
EndotoxinPrymaLab2026-09-19RPT-ET-PL-2609-092
SterilityPrymaLab2026-09-19RPT-ST-PL-2609-092
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-09-19
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-02
M. Phelps
Lab Director · approved for release
Date: 2026-10-03